Pages that link to "Q34268261"
Jump to navigation
Jump to search
The following pages link to A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer (Q34268261):
Displaying 50 items.
- Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test (Q21261272) (← links)
- Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives (Q26768119) (← links)
- Identifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomes (Q26778675) (← links)
- Clinical implications of the intrinsic molecular subtypes of breast cancer (Q26800996) (← links)
- Genomic profiling in luminal breast cancer (Q26862681) (← links)
- Molecular Technologies in the Clinical Diagnostic Laboratory (Q26996463) (← links)
- Advances in the Molecular Analysis of Breast Cancer: Pathway Toward Personalized Medicine (Q27001994) (← links)
- Quantification of HER family receptors in breast cancer (Q27015506) (← links)
- Minireview: Inflammation: An Instigator of More Aggressive Estrogen Receptor (ER) Positive Breast Cancers (Q27016106) (← links)
- Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement (Q27020973) (← links)
- TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer (Q27853147) (← links)
- Signatures of breast cancer metastasis at a glance (Q28071451) (← links)
- Pharmacogenetics and pharmacogenomics as tools in cancer therapy (Q28076200) (← links)
- Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women (Q28077637) (← links)
- From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer? (Q28084982) (← links)
- Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 (Q28085062) (← links)
- Integrated analysis of gene expression, CpG island methylation, and gene copy number in breast cancer cells by deep sequencing (Q28742371) (← links)
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (Q30543788) (← links)
- Integrated analysis of DNA methylation, immunohistochemistry and mRNA expression, data identifies a methylation expression index (MEI) robustly associated with survival of ER-positive breast cancer patients (Q30910707) (← links)
- The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set. (Q30978083) (← links)
- Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling (Q31132241) (← links)
- Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancer (Q31152670) (← links)
- S100β as a serum marker in endocrine resistant breast cancer (Q33556608) (← links)
- Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens (Q33559365) (← links)
- Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics. (Q33573884) (← links)
- Gene regulatory pattern analysis reveals essential role of core transcriptional factors' activation in triple-negative breast cancer (Q33591757) (← links)
- Fewer Reoperations After Lumpectomy for Breast Cancer with Neoadjuvant Rather than Adjuvant Chemotherapy: A Report from the National Cancer Database (Q33628044) (← links)
- Network Analysis Reveals A Signaling Regulatory Loop in the PIK3CA-mutated Breast Cancer Predicting Survival Outcome (Q33631628) (← links)
- Late recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial? (Q33684843) (← links)
- Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment (Q33698446) (← links)
- Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer (Q33712476) (← links)
- Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine (Q33731350) (← links)
- Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer (Q33739303) (← links)
- Insights from Global Analyses of Long Noncoding RNAs in Breast Cancer (Q33787422) (← links)
- Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER /HER2- breast cancer patients: results from the GEICAM 9906 trial. (Q33827057) (← links)
- MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer. (Q33843799) (← links)
- South African Breast Cancer and HIV Outcomes Study: Methods and Baseline Assessment (Q33859760) (← links)
- PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). (Q33883406) (← links)
- Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes (Q33892778) (← links)
- Polarity gene alterations in pure invasive micropapillary carcinomas of the breast (Q33892823) (← links)
- Integrative analysis of copy number and gene expression in breast cancer using formalin-fixed paraffin-embedded core biopsy tissue: a feasibility study (Q33896397) (← links)
- Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes (Q33927000) (← links)
- TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. (Q33954557) (← links)
- Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures (Q34119025) (← links)
- Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer (Q34120668) (← links)
- Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin (Q34123261) (← links)
- Deconstructing the molecular portraits of breast cancer (Q34154147) (← links)
- Long non-coding RNAs differentially expressed between normal versus primary breast tumor tissues disclose converse changes to breast cancer-related protein-coding genes (Q34267035) (← links)
- MicroRNA-584 and the protein phosphatase and actin regulator 1 (PHACTR1), a new signaling route through which transforming growth factor-β Mediates the migration and actin dynamics of breast cancer cells (Q34332277) (← links)
- Predicting response and survival in chemotherapy-treated triple-negative breast cancer. (Q34354538) (← links)